Drug intelligence / Profile preview

JNJ-88998377

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ-88998377 is an investigational small molecule drug developed by Johnson & Johnson (Janssen Research & Development) for the treatment of relapsed and refractory B-cell non-Hodgkin’s lymphoma (NHL), including subtypes such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), mucosa-associated lymphoid tissue lymphoma (MALT lymphoma), follicular lymphoma (FL), and Waldenstrom's macroglobulinemia. The drug is administered orally and acts as a TRPV1 antagonist. It is currently in Phase I clinical trials across multiple countries to determine its safety profile and recommended phase II dose.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on JNJ-88998377.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-88998377.

Explore the full profile